Skyrizi vs Stelara: Which Is Right for You?

When it comes to treating conditions such as psoriasis and psoriatic arthritis, two popular options are Skyrizi and Stelara. Both medications are biologics that work by targeting specific proteins in the body that contribute to inflammation. However, there are some key differences between the two drugs that may make one more suitable for you than the other. In this article, we will compare Skyrizi and Stelara in terms of their effectiveness, side effects, dosing, and cost to help you make an informed decision about which medication is right for you.

Effectiveness

Skyrizi

Skyrizi (risankizumab) is a newer medication that has been shown to be highly effective in treating moderate to severe plaque psoriasis. Clinical trials have demonstrated that Skyrizi can significantly reduce the severity of psoriasis symptoms and improve quality of life for patients.
The mechanism of action of Skyrizi involves targeting the interleukin-23 (IL-23) cytokine, which plays a key role in the inflammatory process in psoriasis. By blocking IL-23, Skyrizi helps to reduce inflammation and skin cell overgrowth associated with the condition.
In addition to plaque psoriasis, Skyrizi has also shown promising results in the treatment of psoriatic arthritis, a related autoimmune condition that affects the joints.

Stelara

Stelara (ustekinumab) is an established medication that has been on the market for longer than Skyrizi. It is also effective in treating moderate to severe plaque psoriasis and psoriatic arthritis. Like Skyrizi, Stelara has been shown to reduce symptoms and improve quality of life for patients.
The mechanism of action of Stelara involves targeting both IL-12 and IL-23 cytokines, which are involved in the immune response and inflammation in psoriasis. By blocking these cytokines, Stelara helps to reduce inflammation and slow down the progression of the disease.
Stelara has also been approved for the treatment of Crohn’s disease and ulcerative colitis, highlighting its versatility in managing various autoimmune conditions.

Side Effects

Skyrizi

Common side effects of Skyrizi include upper respiratory infections, headache, fatigue, and injection site reactions. In some cases, Skyrizi may also increase the risk of infections, including serious infections such as tuberculosis and fungal infections.
It is important for patients taking Skyrizi to be vigilant about monitoring for signs of infection and to seek medical attention if any symptoms develop. Regular follow-up with a healthcare provider can help to ensure that any potential side effects are promptly addressed.
While the risk of serious side effects with Skyrizi is relatively low, it is essential for patients to be aware of the potential risks and benefits of treatment before starting therapy.

Stelara

Common side effects of Stelara include upper respiratory infections, headache, fatigue, and injection site reactions. Stelara may also increase the risk of infections, including serious infections such as tuberculosis and fungal infections. In addition, Stelara has been associated with an increased risk of certain types of cancer, including skin cancer.
Patients taking Stelara should be monitored regularly for signs of infection and cancer, and any concerning symptoms should be reported to a healthcare provider promptly. It is essential for patients to weigh the potential risks and benefits of Stelara treatment with their healthcare provider before initiating therapy.
Despite the potential side effects, many patients find that the benefits of Stelara in managing their psoriasis or psoriatic arthritis outweigh the risks, leading to improved quality of life and symptom control.

Dosing

Skyrizi

Skyrizi is typically administered as a subcutaneous injection once every 12 weeks after an initial loading dose. The loading dose consists of two injections given four weeks apart. Skyrizi can be self-administered or given by a healthcare provider.
The dosing schedule of Skyrizi is designed to provide sustained control of psoriasis symptoms while minimizing the frequency of injections. Patients should follow the recommended dosing regimen and attend regular follow-up appointments to monitor treatment response and any potential side effects.
Self-administration of Skyrizi injections may offer convenience and flexibility for patients, allowing them to manage their treatment from the comfort of their own home. However, proper training and supervision by a healthcare provider are essential to ensure safe and effective administration.

Stelara

Stelara is typically administered as a subcutaneous injection or intravenous infusion. The dosing schedule varies depending on the condition being treated. For plaque psoriasis, the initial dose is typically two injections followed by one injection every 12 weeks. For psoriatic arthritis, the initial dose is typically one injection followed by one injection every 12 weeks.
The dosing flexibility of Stelara allows for personalized treatment plans based on the individual patient’s needs and response to therapy. Healthcare providers can adjust the dosing schedule as needed to optimize treatment outcomes and maintain disease control.
Patients receiving Stelara infusions should be monitored closely during and after treatment to assess for any adverse reactions and ensure the medication’s efficacy. Regular monitoring and communication with a healthcare provider are essential for successful management of psoriasis or psoriatic arthritis with Stelara.

Cost

The cost of Skyrizi and Stelara can vary depending on factors such as insurance coverage, dosage, and pharmacy pricing. Both medications are biologics, which can be expensive. However, there may be financial assistance programs available from the manufacturers to help offset the cost of treatment.
Patients should explore all available resources, including insurance coverage, patient assistance programs, and discount cards, to minimize out-of-pocket expenses associated with Skyrizi or Stelara therapy. Healthcare providers and pharmacists can also provide guidance on cost-saving strategies and alternative treatment options.
By proactively addressing financial concerns and seeking available resources, patients can access the care they need to effectively manage their psoriasis or psoriatic arthritis with Skyrizi or Stelara. Open communication with healthcare providers and support staff is crucial for navigating the financial aspects of treatment and ensuring continuity of care.

In conclusion, both Skyrizi and Stelara are effective treatments for psoriasis and psoriatic arthritis. The decision of which medication is right for you will depend on factors such as your specific condition, treatment goals, and tolerance of potential side effects. It is important to discuss your options with your healthcare provider to determine the best course of treatment for you.

FAQ

1. Which medication is more effective for treating moderate to severe plaque psoriasis?

Skyrizi has been shown to be highly effective in treating moderate to severe plaque psoriasis, significantly reducing the severity of symptoms and improving quality of life for patients.

2. What are the common side effects of both Skyrizi and Stelara?

Both Skyrizi and Stelara may cause common side effects such as upper respiratory infections, headache, fatigue, and injection site reactions. Additionally, both medications may increase the risk of infections, including serious infections such as tuberculosis and fungal infections.

3. How often do patients need to take Skyrizi and Stelara?

Skyrizi is typically administered as a subcutaneous injection once every 12 weeks after an initial loading dose. The loading dose consists of two injections given four weeks apart. On the other hand, Stelara has a dosing schedule that varies depending on the condition being treated, with different initial doses and injection frequencies.

4. Are there any differences in terms of cost between Skyrizi and Stelara?

The cost of Skyrizi and Stelara may vary depending on factors such as insurance coverage and discounts. It is recommended to check with your healthcare provider or insurance company for specific cost information related to these medications.